Tulika Tyagi

Title: Tulika Tyagi: Innovator in Anti-TGFβ Antibodies

Introduction

Tulika Tyagi is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of isoform-selective anti-TGFβ antibodies. Her work is crucial for advancing treatments for fibrosis and other TGFβ-related disorders.

Latest Patents

Tulika Tyagi holds one patent titled "Isoform-selective anti-TGFβ antibodies and methods of use." This invention provides isoform-selective anti-TGFβ antibodies, including anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies. These antibodies are designed for therapeutic applications, particularly in treating fibrosis and various TGFβ-related conditions.

Career Highlights

Tulika is currently employed at Genentech, Inc., a leading biotechnology company known for its innovative approaches to drug development. Her role at Genentech allows her to work on cutting-edge research that has the potential to impact patient care significantly.

Collaborations

Throughout her career, Tulika has collaborated with notable colleagues, including Wei-Ching Liang and Joseph R Arron. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.

Conclusion

Tulika Tyagi's contributions to the field of biotechnology, particularly through her patent on isoform-selective anti-TGFβ antibodies, highlight her role as an innovator. Her work at Genentech, along with her collaborations, positions her as a key figure in advancing treatments for serious medical conditions.